The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review

I. Putu Eka Widyadharma; Clarissa Tertia; Aurelia Vania; Pamela Tiffani; I. Gede Eka Wiratnaya

doi:10.5114/ppn.2024.144603

Streszczenie

3/2024 vol. 33

Artykuł przeglądowy

The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review

I. Putu Eka Widyadharma ¹

,

Clarissa Tertia ²

,

Aurelia Vania ³

,

Pamela Tiffani ¹

,

I. Gede Eka Wiratnaya ⁴

Department of Neurology, Faculty of Medicine, Universitas Udayana, Prof. Dr. IGNG Ngoerah General Hospital, Bali,
Department of Neurology, Eka Hospital, Pekanbaru, Indonesia
Atma Jaya Neuroscience and Cognitive Center, Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
Department of Orthopedic, Faculty of Medicine, Universitas Udayana Prof. Dr. IGNG Ngoerah General Hospital, Bali, Indonesia

DOI: https://doi.org/10.5114/ppn.2024.144603

Data publikacji online: 2024/10/31

Pełna treść artykułu

AMA

Widyadharma I, Tertia C, Vania A, Tiffani P, Wiratnaya I. The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2024;33(3):172-177. doi:10.5114/ppn.2024.144603.

APA

Widyadharma, I., Tertia, C., Vania, A., Tiffani, P., & Wiratnaya, I. (2024). The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 33(3), 172-177. https://doi.org/10.5114/ppn.2024.144603

Chicago

Widyadharma, I. Putu Eka, Clarissa Tertia, Aurelia Vania, Pamela Tiffani, and I. Gede Eka Wiratnaya. 2024. "The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review". Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii 33 (3): 172-177. doi:10.5114/ppn.2024.144603.

Harvard

Widyadharma, I., Tertia, C., Vania, A., Tiffani, P., and Wiratnaya, I. (2024). The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 33(3), pp.172-177. https://doi.org/10.5114/ppn.2024.144603

MLA

Widyadharma, I. Putu Eka et al. "The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review." Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, vol. 33, no. 3, 2024, pp. 172-177. doi:10.5114/ppn.2024.144603.

Vancouver

Widyadharma I, Tertia C, Vania A, Tiffani P, Wiratnaya I. The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2024;33(3):172-177. doi:10.5114/ppn.2024.144603.

Streszczenie

The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review

Udostępnij

Dostępne w

Indeksowane w

Zintergrowane z

Zasady redakcyjne